Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Platinum-Resistant ovarian cancer?

NCT ID NCT07278336

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 4 times

Summary

This early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tumors. Participants will receive the drug through an IV and will be closely monitored with frequent tests and scans over about 3 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABBV-901 (an investigational drug) and bevacizumab (a standard cancer therapy)
What this could lead to
If successful, this could point toward a new treatment option for ovarian cancer that is resistant to platinum-based therapies.
What could go wrong
This is an early Phase 1 trial, so safety and effectiveness are not yet proven. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 219 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization \[WHO\] criteria). * Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy). * Prior anticancer therapy: * Must have received appropriate standard of care therapy and be appropriate for participation in a Phase I study in the opinion of the investigator. * Platinum-resistant, high grade serous EOC cannot have had more than 2 prior lines of therapy, since the development of platinum resistance or ineligibility. * For participants enrolled in backfill, subjects must provide consent to paired biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion. Exclusion Criteria: * Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, clear cell, mucinous, or borderline ovarian tumor. * Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor. * Prior history of Grade \>= 2 ILD or pneumonitis. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan. * Must not have systemically used known strong cytochrome P450 (CYP)3A inhibitors or inducers within 14 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of the study drug through the end of the DLT observation period. If clinically indicated, strong CYP3A inhibitors and inducers may be used with caution after the dose-limiting toxicity (DLT) period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube serous adenocarcinoma ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center /ID# 282600

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Hadassah Medical Center-Hebrew University /ID# 278420

    RECRUITING

    Jerusalem, 91120, Israel

  • NEXT Oncology - San Antonio /ID# 278606

    RECRUITING

    San Antonio, Texas, 78229, United States

  • National Cancer Center Hospital East /ID# 278604

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • New Zealand Clinical Research (Christchurch) /ID# 281467

    NOT_YET_RECRUITING

    Christchurch, Canterbury, 8011, New Zealand

  • Next Virginia /ID# 278607

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Qilu Hospital Of Shandong University /ID# 283564

    NOT_YET_RECRUITING

    Jinan, Shandong, 250014, China

  • Rambam Health Care Campus /ID# 278418

    RECRUITING

    Haifa, 3109601, Israel

  • Saitama Medical University International Medical Center /ID# 278437

    RECRUITING

    Hidaka, Saitama, 350-1298, Japan

  • Sarah Cannon Research Institute at HealthONE /ID# 278785

    RECRUITING

    Denver, Colorado, 80218, United States

  • Shandong Cancer Hospital /ID# 283566

    NOT_YET_RECRUITING

    Jinan, Shandong, 250117, China

  • Shizuoka Cancer Center /ID# 278538

    RECRUITING

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Start Mountain Region /ID# 278609

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Sun Yat-Sen University Cancer Center /ID# 282505

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Taipei Veterans General Hospital /ID# 281349

    RECRUITING

    Taipei, 112, Taiwan

  • The Chaim Sheba Medical Center /ID# 278416

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • University of Chicago Medical Center /ID# 278295

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.